19-Hydroxy-7a-homo-PGI.sub.1 and 19-hydroxy-19-methyl-7a-homo-PGI.sub.1 compounds

Abstract
The present invention provides novel 19-hydroxy-7a-homo-PGI.sub.1 19-hydroxy-19-methyl-7a-homo-PGI.sub.1 compounds which are useful for pharmacological purposes, e.g., anti-asthmatic indications.
Description

BACKGROUND OF THE INVENTION
The present invention provides novel prostacyclin analogs. Particularly, the present invention relates to prostacyclin in analogs substituted at the C-19 position by hydroxy.
Particularly, the present invention relates to 19-hydroxy-7a-homo-PGI.sub.1 and 19-hydroxy-19-methyl-7a-homo-PGI.sub.1 compounds. The novel prostacyclin analogs are useful for pharmacological purposes, e.g., as anti-asthmatic agents. The preparation and use of these compounds is incorporated herein by reference from U.S. Pat. Nos. 4,225,507 and 4,225,508, each issued Sept. 30, 1980.
PRIOR ART
For background on prostacyclin, see for example R. A. Johnson, et al., Prostaglandins 12, 915-928 (1976) and R. A. Johnson, et al, J. Am. Chem. Soc. 100, 7690-7704 (1978), and, as to pharmacological activity, the references cited therein. For analogs of prostacyclin, see, for example, J. Fried, et al, Proc. Natl. Acad. Sci. U.S.A. 74, 2199-2203, K. C. Nicolaou, et al, J.C.S. Chem. Comm. 1977, 331-332, N. A. Nelson, J. Am. Chem. Soc. 99, 7362-7363 (1977), and K. Kojima, et al, Tet. Lette., 1978, (1977), and K. Kojima, et al, Tet. Lett., 1978, 3743-3746. Regarding the nomenclature for analogs of PGI.sub.2, see R. A. Johnson, et al, Prostaglandins 15, 737-740 (1978).
SUMMARY OF THE INVENTION





The present invention particularly provides a prostacyclin-type compound of the formula ##STR1## wherein W is H or --CH.sub.3 ; wherein A.sub.1 is --O-- (oxa) and E.sub.2 is --CH.sub.2 CH.sub.2 --;
wherein L.sub.2 is --(CH.sub.2).sub.j --, wherein j is one to 4, inclusive;
wherein M.sub.1 is ##STR2## wherein Q is oxo, .alpha.--H:.beta.--H, .alpha.--OH:.beta.--R.sub.4, or .alpha.--R.sub.4 :.beta.--OH,
wherein R.sub.4 is hydrogen or alkyl of one to 4 carbon atoms, inclusive,
wherein R.sub.1 is
(1) --COOR.sub.3,
(2) --CH.sub.2 OH,
(3) --CH.sub.2 N(R.sub.7)(R.sub.8),
(4) --CO--N(R.sub.7)(R.sub.8),
(5) --CO--NH--SO.sub.2 --R.sub.15, or
(6) tetrazolyl,
wherein R.sub.3 is
(a) hydrogen,
(b) alkyl of one to 12 carbon atoms, inclusive,
(c) cycloalkyl of 3 to 10 carbon atoms, inclusive,
(d) aralkyl of 7 to 12 carbon atoms, inclusive,
(e) phenyl,
(f) phenyl substituted with one, 2, or 3 chloro or alkyl groups of one to 3 carbon atoms, inclusive;
(g) --(Ph)--CO--CH.sub.3,
(h) --(p--Ph)--NH--CO--(p--Ph)--NH--CO--CH.sub.3,
(i) --(p--Ph)--NH--CO--(p--Ph),
(j) --(p--Ph)--NH--CO--CH.sub.3,
(k) --(p--Ph)--NH--CO--NH.sub.2,
(l) --(p--Ph)--CH.dbd.N--NH--CO--NH.sub.2,
(m) .beta.-naphthyl,
(n) --CH.sub.2 --CO--R.sub.16,
wherein --(Ph)-- is inter-phenylene and --(p--Ph) is inter-para-phenylene or para-phenyl;
wherein R.sub.16 is phenyl, p-bromophenyl, p-biphenylyl, p-nitrophenyl, p-benzamidophenyl, or 2-naphthyl, or
(o) a pharmacologically acceptable cation; wherein R.sub.7 and R.sub.8 are hydrogen, alkyl of one to 12 carbon atoms, inclusive, benzyl, or phenyl, being the same or different, and wherein R.sub.15 is hydrogen, alkyl of one to 12 carbon atoms, inclusive, phenyl, phenyl-substituted with one, 2, or 3 chloro or alkyl groups of one to 3 carbon atoms, inclusive, or phenyl substituted with hydroxycarbonyl or alkoxycarbonyl of one to 4 carbon atoms, inclusive,
wherein R.sub.2 is hydrogen, hydroxyl, or hydroxymethyl,
wherein R.sub.5 and R.sub.6 are hydrogen, alkyl of one to 4 carbon atoms, inclusive, or fluoro, being the same or different, with the proviso that one of R.sub.5 and R.sub.6 is fluoro only when the other is hydrogen or fluoro, and
wherein X is
(1) trans--CH.dbd.CH--,
(2) cis--CH.dbd.CH--,
(3) --C.tbd.C--, or
(4) --CH.sub.2 CH.sub.2 --.
with the further proviso that when R.sub.1 is --COOR.sub.3 wherein R.sub.3 is hydrogen or alkyl of one to 12 carbon atoms, inclusive; --CH.sub.2 OH; --CON(R.sub.7)(R.sub.8); or tetrazolyl; one of R.sub.5 or R.sub.6 is other than hydrogen.
Claims
  • 1. A prostacyclin-type compound of the formula ##STR3## wherein W is H or CH.sub.3 ; wherein A.sub.1 is --O-- (oxa) and E.sub.2 is --CH.sub.2 CH.sub.2 --;
  • wherein L.sub.2 is --(CH.sub.2).sub.j --, wherein j is one to 4, inclusive;
  • wherein M.sub.1 is ##STR4## wherein Q is oxo, .alpha.--H:.beta.--H, .alpha.--OH:.beta.--R.sub.4, or .alpha.--R.sub.4 :.beta.--OH,
  • wherein R.sub.4 is hydrogen or alkyl of one to 4 carbon atoms, inclusive,
  • wherein R.sub.1 is
  • (1) --COOR.sub.3,
  • (2) --CH.sub.2 OH,
  • (3) --CH.sub.2 N(R.sub.7)(R.sub.8),
  • (4) --CO--N(R.sub.7)(R.sub.8),
  • (5) --CO--NH--SO.sub.2 --R.sub.15, or
  • (6) tetrazolyl,
  • wherein R.sub.3 is
  • (a) hydrogen,
  • (b) alkyl of one to 12 carbon atoms, inclusive,
  • (c) cycloalkyl of 3 to 10 carbon atoms, inclusive,
  • (d) aralkyl of 7 to 12 carbon atoms, inclusive,
  • (e) phenyl,
  • (f) phenyl substituted with one, 2, or 3 chloro or alkyl groups of one to 3 carbon atoms, inclusive;
  • (g) --(Ph)--CO--CH.sub.3,
  • (h) --(p--Ph)--NH--CO--(p--Ph)--NH--CO--CH.sub.3,
  • (i) --(p--Ph)--NH--CO--(p--Ph),
  • (j) --(p--Ph)--NH--CO--CH.sub.3,
  • (k) --(p--Ph)--NH--CO--NH.sub.2,
  • (l) --(p--Ph)--CH.dbd.N--NH--CO--NH.sub.2,
  • (m) .beta.-naphthyl,
  • (n) --CH.sub.2 --CO--R.sub.16,
  • wherein --(Ph)-- is inter-phenylene and --(p--Ph) is inter-para-phenylene or para-phenyl;
  • wherein R.sub.16 is phenyl, p-bromophenyl, p-biphenylyl, p-nitrophenyl, p-benzamidophenyl, or 2-naphthyl, or
  • (o) a pharmacologically acceptable cation; wherein R.sub.7 and R.sub.8 are hydrogen, alkyl of one to 12 carbon atoms, inclusive, benzyl, or phenyl, being the same or different, and wherein R.sub.15 is hydrogen, alkyl of one to 12 carbon atoms, inclusive, phenyl, phenyl-substituted with one, 2, or 3 chloro or alkyl groups of one to 3 carbon atoms, inclusive, or phenyl substituted with hydroxycarbonyl or alkoxycarbonyl of one to 4 carbon atoms, inclusive,
  • wherein R.sub.2 is hydrogen, hydroxyl, or hydroxymethyl,
  • wherein R.sub.5 and R.sub.6 are hydrogen, alkyl of one to 4 carbon atoms, inclusive, or fluoro, being the same or different, with the proviso that one of R.sub.5 and R.sub.6 is fluoro only when the other is hydrogen or fluoro, and
  • wherein X is
  • (1) trans--CH.dbd.CH--,
  • (2) cis--CH.dbd.CH--,
  • (3) --C.tbd.C--, or
  • (4) --CH.sub.2 CH.sub.2 --,
  • with the further proviso that when R.sub.1 is --COOR.sub.3 wherein R.sub.3 is hydrogen or alkyl of one to 12 carbon atoms, inclusive; --CH.sub.2 OH; --CON(R.sub.7)(R.sub.8); or tetrazolyl; one of R.sub.5 or R.sub.6 is other than hydrogen.
  • 2. A compound of claim 1, wherein W is H.
  • 3. A compound of claim 1, wherein W is --CH.sub.3.
DESCRIPTION

The present invention is a continuation-in-part application of U.S. Ser. No. 126,512, filed Mar. 3, 1980 now U.S. Pat. No. 4,328,156, issued May 4, 1982, which is a division of Ser. No. 054,720, filed July 5, 1979, issued Sept. 30, 1980 as U.S. Pat. No. 4,225,507.

US Referenced Citations (2)
Number Name Date Kind
4123441 Johnson et al. Oct 1978
4230721 Gandolfi et al. Oct 1980
Divisions (1)
Number Date Country
Parent 054720 Jul 1979
Continuation in Parts (1)
Number Date Country
Parent 126512 Mar 1980